Business
Monday, August 29, 2016
Mylan's generic EpiPen will bite into earnings
Putting out a cheaper generic version of its EpiPen could cut Mylan's earnings by up to 10 percent, says Bernstein senior analyst Ronny Gal.
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment